Dear Sir, We are grateful to Professor Karamanakos for his suggestions about our interpretation of the anxiolytic-like effect of chlorpheniramine (CPA).
Karamanakos et al. suggested that high dose of CPA produces hyperlocomotion and hypothermia through the activation of 5-HT1A receptors in the rat (Karamanakos et al. 2004 ). Moreover, 5-HT1A receptor agonist and antagonist enhanced or blocked, respectively, the effect of CPA. Based on these results, they suggested that CPA produces its effect though the activation of the postsynaptic 5-HT1A receptors.
According to his interpretation, the low dose of CPA could bind to presynaptic 5-HT1A receptors and produce anxiolytic-like effects in mice because higher dose of CPA binds to postsynaptic 5-HT1A receptors (Karamanakos et al. 2004 ). Since 5-HT1A receptors are coupled with Gi/o proteins (Blier et al. 1993) , the activation of presynaptic 5-HT1A receptors produces the reduction of neurotransmitter release from nerve endings (Guilloux et al. 2006) . We reported that local application of CPA into prefrontal cortex increases the release of cortical 5-HT which suggests that the activation of 5-HT1A receptors was not involved in the effect of CPA, at least in our study. Furthermore, we could not find any reports indicating the affinity of chlorpheniramine for the 5-HT1A receptor in vitro.
At this time, it is difficult to conclude that the effect of CPA is mediated by the activation of 5-HT1A receptors, especially as CPA has been reported to bind to 5-HT2C receptors (Sanders-Bush and Breeding 1988) . However, we acknowledge the need to perform a receptor binding study to clarify whether CPA has any binding affinity to 5-HT1A receptors.
